Mammoth Biosciences stock

Mammoth Biosciences Stock

HealthTech
Looking to sell Mammoth Biosciences Stock or Options? Get a free valuation
Founded: 2017Funding to Date: $365M
Visit website

Mammoth Biosciences is a biotechnology company that aims to develop long-lasting curative therapies along with decentralized precision diagnostics. The company employs its proprietary ultracompact proteins for in vivo gene editing in hard-to-reach tissues. It uses both nuclease applications and introduces new editing techniques beyond double-stranded breaks, such as base editing, gene writing, and epigenetic editing. This enables healthcare professionals to drastically improve the lives of their patients.

Investors Include:

University of California, Decheng Capital, Tachyon Ventures, Tectonic Capital, K50 Ventures, Berkeley Frontier Fund, Plum Alley Investments, Boom Capital Ventures, Sixth Street Partners, Wireframe Ventures, Redmile Group, DHVC, Amazon.com, Mission Bay Capital, Berkeley, 8VC, Kairos HQ, Mission BioCapital, Brook Byers, Plug and Play Tech Center, Verily Life Sciences, Foresite Capital, California Innovation Fund, Senator Investment Group, NFX.

Own Mammoth Biosciences stock or options?

Get an instant valuation

  • Completely free
  • 100% confidential & secure
  • Takes less than a minute
100% private & secure